An in situ autologous tumor vaccination with combined radiation therapy and TLR9 agonist therapy
about
Radiotherapy combination opportunities leveraging immunity for the next oncology practiceUnlocking the combination: potentiation of radiation-induced antitumor responses with immunotherapyCombining radiotherapy and cancer immunotherapy: a paradigm shiftConsiderations for combined immune checkpoint modulation and radiation treatment.Biodegradable microparticles loaded with doxorubicin and CpG ODN for in situ immunization against cancer.Clinical opportunities in combining immunotherapy with radiation therapy.Locally advanced lung cancer: an optimal setting for vaccines and other immunotherapies.Application potential of toll-like receptors in cancer immunotherapy: Systematic review.The confluence of radiotherapy and immunotherapy.In situ vaccination: Cancer immunotherapy both personalized and off-the-shelf.In situ vaccination for the treatment of cancer.Immunotherapy and stereotactic ablative radiotherapy (ISABR): a curative approach?Rationale and evidence to combine radiation therapy and immunotherapy for cancer treatment.Trial Watch: Toll-like receptor agonists for cancer therapy.TRPM5 mediates acidic extracellular pH signaling and TRPM5 inhibition reduces spontaneous metastasis in mouse B16-BL6 melanoma cells.Stimulating Innate Immunity to Enhance Radiation Therapy-Induced Tumor Control.Danger signals: Chemotherapy enhancers?Abscopal, immunological effects of radiotherapy: Narrowing the gap between clinical and preclinical experiences.A rapid and systemic complete response to stereotactic body radiation therapy and pembrolizumab in a patient with metastatic renal cell carcinoma.
P2860
Q26738443-18A6639A-1B56-4001-8464-2C4269AA4622Q27001216-7B19851A-58F5-48CD-8108-F9C49A679957Q27021428-B85E0263-5237-41E4-AC03-DBA8F6BECD89Q34174871-979EA136-3242-4A41-9D15-A60D7E2C8FC5Q34871657-FFF8DEB3-CD0C-4459-B514-1949D9C13D07Q36449873-1BCB7D44-C5A1-4787-8EC2-A756618D04DEQ36946100-0C5C8790-9011-4897-A82C-3BFD382CB470Q37205171-47F16CBC-D302-47C0-A6A4-BCAFEDFF9565Q38054113-2ADD89B8-285D-425D-9AD2-5E760B75F8D8Q38657642-F0AA80BA-4CCE-4E7A-9B4C-18B9C11433F4Q38727470-57D5C6D7-0F44-4E47-9FA5-C582ACCE54EDQ38763935-21AB428D-5364-4666-BB39-7DCFE8D88830Q38981347-D49D83A0-C054-4A6E-A7A3-9709F26E61DFQ42969291-5BC6DCFD-FF1E-4986-AEB2-48A939CA0628Q43125262-337DFDA9-30E3-4546-95EB-BC452EB58441Q46189367-269E36A6-FE64-4473-9E82-C947D33634A3Q47659090-BF8C0CF3-FB9D-4668-9F06-82C7DF46381FQ47899811-10836329-8668-4D1F-9D00-4476D3ACFD3EQ53186440-1320E0E1-1678-4A96-A712-9DFB9E4E61CD
P2860
An in situ autologous tumor vaccination with combined radiation therapy and TLR9 agonist therapy
description
2012 nî lūn-bûn
@nan
2012 թուականին հրատարակուած գիտական յօդուած
@hyw
2012 թվականին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
An in situ autologous tumor va ...... erapy and TLR9 agonist therapy
@ast
An in situ autologous tumor va ...... erapy and TLR9 agonist therapy
@en
An in situ autologous tumor va ...... erapy and TLR9 agonist therapy
@nl
type
label
An in situ autologous tumor va ...... erapy and TLR9 agonist therapy
@ast
An in situ autologous tumor va ...... erapy and TLR9 agonist therapy
@en
An in situ autologous tumor va ...... erapy and TLR9 agonist therapy
@nl
prefLabel
An in situ autologous tumor va ...... erapy and TLR9 agonist therapy
@ast
An in situ autologous tumor va ...... erapy and TLR9 agonist therapy
@en
An in situ autologous tumor va ...... erapy and TLR9 agonist therapy
@nl
P2093
P2860
P1433
P1476
An in situ autologous tumor va ...... erapy and TLR9 agonist therapy
@en
P2093
Chandan Guha
Ekambar R Kandimalla
Huagang Zhang
Hui Bin Sun
Laibin Liu
Sudhir Agrawal
P2860
P304
P356
10.1371/JOURNAL.PONE.0038111
P407
P577
2012-01-01T00:00:00Z